Cochrane · systematic review · CD012369
Antiplatelet agents for the treatment of deep venous thrombosis
Flumignan, CDQ, Nakano, LCU, Baptista-Silva, JCC, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
VascularAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
18
current version
GRADE rated
16
No studies
2
Included studies
NR
No studies 2 · 11.1%Ungraded 0 · 0%Very low 11 · 61.1%Low 1 · 5.6%Moderate 4 · 22.2%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Acute DVT ‐ antiplatelet agents plus BMP compared to BMP alone for the treatment of DVT
Population: people requiring treatment for acute DVT
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Recurrent VTE Acute DVT ‐ antiplatelet agents plus BMP vs BMP alone | no estimate extracted | 1 study · 500 participants | Very low Downgraded: risk of bias, imprecision |
Major bleeding Acute DVT ‐ antiplatelet agents plus BMP vs BMP alone | no estimate extracted | 1 study · 500 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Pulmonary embolism Acute DVT ‐ antiplatelet agents plus BMP vs BMP alone | no estimate extracted | 1 study · 500 participants | Very low Downgraded: risk of bias, imprecision |
Mortality ‐ early and intermediate Acute DVT ‐ antiplatelet agents plus BMP vs BMP alone | no estimate extracted | 1 study · 500 participants | Very low Downgraded: risk of bias, imprecision |
Post‐thrombotic syndrome Acute DVT ‐ antiplatelet agents plus BMP vs BMP alone | RR 0.74 [0.61, 0.91] | 1 study · 500 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Adverse events Acute DVT ‐ antiplatelet agents plus BMP vs BMP alone | RR 2.88 [1.06, 7.8] | 1 study · 500 participants | Very low Downgraded: risk of bias, imprecision |
Chronic DVT ‐ antiplatelet agents plus BMP compared to BMP alone for the treatment of DVT
Population: people requiring treatment for chronic DVT
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Recurrent VTE ‐ early and intermediate Chronic DVT ‐ antiplatelet agents plus BMP vs BMP alone | RR 0.12 [0.05, 0.34] | 1 study · 224 participants | Very low Downgraded: risk of bias, imprecision |
Major bleeding Chronic DVT ‐ antiplatelet agents plus BMP vs BMP alone | no estimate extracted | 1 study · 224 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Pulmonary embolism Chronic DVT ‐ antiplatelet agents plus BMP vs BMP alone | no estimate extracted | 1 study · 224 participants | Very low Downgraded: risk of bias, imprecision |
Mortality ‐ early and intermediate Chronic DVT ‐ antiplatelet agents plus BMP vs BMP alone | no estimate extracted | 1 study · 224 participants | Very low Downgraded: risk of bias, imprecision |
Post‐thrombotic syndrome Chronic DVT ‐ antiplatelet agents plus BMP vs BMP alone | no estimate extracted | NR | No studies |
Adverse events Chronic DVT ‐ antiplatelet agents plus BMP vs BMP alone | no estimate extracted | 1 study · 224 participants | Very low Downgraded: risk of bias, imprecision |
Chronic DVT ‐ antiplatelet agents plus BMP compared to BMP plus placebo for the treatment of DVT
Population: people requiring treatment for chronic DVT
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Recurrent VTE ‐ early, intermediate and long term Chronic DVT ‐ antiplatelet agents plus BMP vs BMP plus placebo | RR 0.65 [0.43, 0.96] | 4 studies · 901 participants | Low Downgraded: risk of bias, imprecision |
Major bleeding Chronic DVT ‐ antiplatelet agents plus BMP vs BMP plus placebo | RR 0.98 [0.29, 3.34] | 1 study · 583 participants | Moderate Downgraded: imprecision |
Pulmonary embolism (fatal/non‐fatal) Chronic DVT ‐ antiplatelet agents plus BMP vs BMP plus placebo | RR 0.52 [0.23, 1.14] | 1 study · 583 participants | Moderate Downgraded: imprecision |
Mortality ‐ intermediate and long term Chronic DVT ‐ antiplatelet agents plus BMP vs BMP plus placebo | RR 0.48 [0.21, 1.06] | 3 studies · 649 participants | Moderate Downgraded: imprecision |
Post‐thrombotic syndrome Chronic DVT ‐ antiplatelet agents plus BMP vs BMP plus placebo | no estimate extracted | NR | No studies |
Adverse events Chronic DVT ‐ antiplatelet agents plus BMP vs BMP plus placebo | RR 1.57 [0.34, 7.19] | 2 studies · 621 participants | Moderate Downgraded: imprecision |